Genetic screening for the predisposition to venous thromboembolism: A cost-utility analysis of clinical practice in the italian health care system

Value in Health

Volumn 16, Issue 6, 2013, Pages 909-921

  Compagni, Amelia ^a,b   Melegaro, Alessia ^a,b   Tarricone, Rosanna ^a,b  

^a BOCCONI UNIVERSITY   (Italy)

^b Centre for Research in Health and Social Care Management (CeRGAS)   (Italy)

Author keywords

cost utility analysis genetic testing Italy venous thromboembolism

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE PREDISPOSITION; FEMALE; GENETIC SCREENING; GYNECOLOGIST; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL DISCHARGE; HUMAN; ITALY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNWANTED PREGNANCY; VENOUS THROMBOEMBOLISM;

COST-UTILITY ANALYSIS; GENETIC TESTING; ITALY; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; COSTS AND COST ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; ITALY; MIDDLE AGED; MODELS, THEORETICAL; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PROTHROMBIN; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84884290964     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.05.003     Document Type: Article

References (71)

1. House of Lords Science and Technology Committee Genomic Medicine 2009 The Stationery Office London
2. H. Burton Genetics and Mainstream Medicine 2011 PHG Foundation Cambridge
3. N.F. Col The use of gene test to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant? Med Decis Making 23 2003 441 448
4. E. Zika, D. Gurwitz, and D. Ibarreta Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impacts in the EU 2006 Office of the Official Publications of the EU Communities Luxembourg
5. E. Mansfield, T.J. O'Leary, and S.I. Gutman Food and drug administration of in vitro diagnostic devices J Mol Diagn 7 2005 2 7
6. S.D. Ramsey, D.L. Veenstra, and L.P. Garrison Jr. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests Am J Manag Care 12 2006 197 202
7. S. Hogarth, G. Javitt, and D. Melzer The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues Annu Rev Genomics Hum Genet 9 2008 161 182
8. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, eds., Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford, 2004:217-33.
9. S.M. Teutsch, L.A. Bradley, and G.E. Palomaki The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group Genet Med 11 2009 3 14
10. J.J. Carlson, N.B. Henrikson, and D.L. Veenstra Economic analyses of human genetics services: a systematic review Genet Med 7 2005 519 523
11. W. Rogowski Genetic screening by DNA technology: a systematic review of health economic evidence Int J Technol Assess Health Care 22 2006 327 337
12. S.D. Grosse, S. Wordsworth, and K. Payne Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis Genet Med 10 2008 648 654
13. M. Drummond, A. Griffin, and R. Tarricone Economic evaluation for devices and drugs - same or different? Value Health 12 2009 402 404
14. K.B. Frønsdal, K. Facey, and M. Klemp Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes Int J Technol Assess Health Care 26 2010 309 316
15. M.L. Berger, M. Mamdani, D. Atkins, and M.L. Johnson Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - part I Value Health 12 2009 1044 1052
16. E. Cox, B.C. Martin, and T. Van Staa Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of non-randomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force-part II Value Health 12 2009 1053 1061
17. M.L. Berger, N. Dreyer, and F. Anderson Prospective observational studies to assess comparative effectiveness: the ISPOR Good Research Practices Task Force Report Value Health 15 2012 217 230
18. M.L. Johnson, W. Crown, and B.C. Martin Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - part III Value Health 12 2009 1062 1073
19. R.H. White The epidemiology of venous thromboembolism Circulation 107 23, Suppl. 1 2003 I4 I8
20. F.A. Anderson Jr, H.B. Wheeler, and R.J. Goldberg A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study Arch Intern Med 151 1991 933 938
21. M.D. Silverstein, J.A. Heit, and D.N. Mohr Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 158 1998 585 593
22. M. Nordstrom, B. Lindblad, and D. Bergqvist A prospective study of the incidence of deep-vein thrombosis within a defined urban population J Intern Med 232 1992 155 160
23. F.A. Spencer, C. Emery, and D. Lessard The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism J Gen Intern Med 21 2006 722 727
24. E. Oger Incidence of venous thromboembolism: a community-based study in Western France. EPIGETBO Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale Thromb Haemost 83 2000 657 660
25. A.T. Cohen, R.A. Edmondson, and M.J. Phillips The changing pattern of venous thromboembolic disease Haemostasis 26 1996 65 71
26. B. Lindblad, N.H. Sternby, and D. Bergqvist Incidence of venous thromboembolism verified by necropsy over 30 years BMJ 302 1991 709 711
27. D.A. Sandler, and J.F. Martin Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 82 1989 203 205
28. R. Gohil, G. Peck, and P. Sharma The genetics of venous thromboembolism: a meta-analysis involving approximately 120,000 cases and 180,000 controls Thromb Haemost 102 2009 360 370
29. B. Dallapiccola, I. Torrente, A. Morena, and R. Mingarelli Censimento delle strutture di Genetica Medica e dei test genetici in Italia-Anno 2004 Analysis 6/7 2006 263 278
30. B. Dallapiccola, E. Agolini, and A. Morena Censimento 2007 delle attività delle strutture di Genetica Medica in Italia Analysis 4/5 2009 207 232
31. Consensus Conference Roma, 18-19 September 2008. Prevenzione delle complicanze trombotiche associate all'uso di estro progestinici in età riproduttiva. Available from: http://www.snlg-iss.it/cms/files/CC-EP- trombofilia.pdf. [Accessed May 30, 2012].
32. W.W. Grody, J.H. Griffin, and A.K. Taylor American College of Medical Genetics consensus statement on factor V Leiden mutation testing Genet Med 3 2001 139 148
33. European Genetics Foundation, Cardiovascular Disease Educational and Research Trust, and International Union of Angiology Thrombophilia and venous thromboembolism: international consensus statement. Guidelines according to scientific evidence Int Angiol 24 2005 1 26
34. P. Clark, S. Twaddle, and I.D. Walker Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women Lancet 359 2002 1919 1920
35. K.J. Smith, B.S. Monsef, and M.V. Ragni Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis Thromb Haemost 100 2008 447 452
36. O. Wu, L. Robertson, and S. Twaddle Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis Br J Haematol 131 2005 80 90
37. Ø. Lidegaard, B. Edström, and S. Kreiner Oral contraceptives and venous thromboembolism: a five-year national case-control study Contraception 65 2002 187 196
38. P.O. Hansson, J. Sörbo, and H. Eriksson Recurrent venous thromboembolism after deep vein thrombosis Arch Intern Med 160 2000 769 774
39. K.J. Smith, and S, Monsef Brenna Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis Thromb Haemost 100 2008 447 452
40. M. Marchetti, S. Quaglini, and G. Barosi Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A QJM 94 2001 365 372
41. H.T. Sørensen, E. Horvath-Puho, and L. Pedersen Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study Lancet 370 2007 1773 1779
42. F.R. Rosendaal Risk factors for venous thrombotic disease Thromb Haemost 82 1999 610 619
43. Department of Reproductive Health, World Health Organization Medical Eligibility Criteria for Contraceptive Use 4th ed. 2010 World Health Organization Geneva Available from: http://www.who.int/reproductivehealth/ publications/family-planning/9789241563888/en/index.html [Accessed May 30, 2012]
44. Ø. Lidegaard, E. Løkkegaard, A.L. Svendsen, and C. Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890
45. M. Carrier, G. Le Gal, P.S. Wells, and M.A. Rodger Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism Ann Intern Med 152 2010 578 589
46. O. Wu, L. Robertson, and S. Twaddle Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study Health Technol Assess 10 2006 1 110
47. L. Manzoli, C. De Vito, and C. Marzuillo Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis Drug Saf 35 2012 191 205
48. P. Prandoni, A.W. Lensing, and A. Cogo The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
49. V. Pengo, A.W. Lensing, and M.H. Prins Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med 350 2004 2257 2264
50. C. Laczkovics, H. Grafenhofer, and A. Kaider Risk of recurrence after a first venous thromboembolic event in young women Haematologica 92 2007 1201 1207
51. R.S. Duriseti, and M.L. Brandeau Cost-effectiveness of strategies for diagnosing pulmonary embolism among emergency department patients presenting with undifferentiated symptoms Ann Emerg Med 56 2010 321 332
52. J.J. O'Meara, R.A. McNutt, and A.T. Evans A decision analysis of streptokinase plus heparin as compared to heparin alone for deep vein thrombosis N Engl J Med 330 1994 1864 1869
53. D.A. Cadilhac, H.M. Dewey, and T. Vos The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS) Health Qual Life Outcomes 8 2010 49
54. P. Clarke, A. Gray, and R. Holman Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making 22 2002 340 349
55. S.P. McKenna, J. Ratcliffe, D.M. Meads, and J.E. Brazier Development and validation of a preference-based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses Health Qual Life Outcomes 6 2008 65
56. G. Amaral, D.G. Foster, and M.A. Biggs Public savings from the prevention of unintended pregnancy: a cost analysis of family planning services in California Health Serv Res 42 2007 1960 1980
57. D.A. Lane, P.M. Mannucci, and K.A. Bauer Inherited thrombophilia: part 1 Thromb Haemost 76 1996 651 662
58. D.A. Lane, P.M. Mannucci, and K.A. Bauer Inherited thrombophilia: part 2 Thromb Haemost 76 1996 824 834
59. ISTAT. Cause di morte Anno 2002. Annuario n. 18 - 2007. Available from: http://www3.istat.it/dati/catalogo/20070405-00/ann-07-18-cause-di-morte-2002. pdf. [Accessed May 30, 2012].
60. P. Kind, P. Dolan, C. Gudex, and A. Williams Variations in population health status: results from a United Kingdom national questionnaire survey BMJ 316 1998 736 741
61. C.M. Kessler The link between cancer and venous thromboembolism: a review Am J Clin Oncol 32 4, Suppl. 2009 S3 S7
62. AIFA Prontuario Farmaceutico Nazionale 2005 AIFA Rome
63. National Institute for Clinical Excellence Guide to the Methods of Technology Appraisal 2004 National Institute for Clinical Excellence London
64. A.H. Briggs Holding uncertainty in economic evaluation and presenting the results M.F. Drummond, A. McGuire, Economic Evaluation in Health Care: Merging Theory with Practice 2001 Oxford University Press Oxford 172 214
65. J. Appleby, N. Devlin, and D. Parkin NICE's cost effectiveness threshold BMJ 335 2007 358 359
66. M.J. Jang, W. Choi, and S.-M. Bang Metabolic syndrome is associated with venous thromboembolism in the Korean population Arterioscler Thromb Vasc Biol 29 2009 311 315
67. R.D. Smith Is regret theory an alternative basis for estimating the value of healthcare interventions? Health Policy 37 2000 105 115
68. I. Hozo, and B. Djulbegovic When is diagnostic testing inappropriate or irrational? Acceptable regret approach Med Decis Making 28 2008 540 553
69. A. Briggs, M. Schulpher, and K. Claxton Decision Modelling for Health Economic Evaluation 2006 Oxford University Press Oxford
70. Z. Philips, L. Bojke, and M. Sculpher Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment Pharmacoeconomics 24 2006 355 371
71. S.D. Grosse Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Expert Rev Pharmacoecon Outcomes Res 8 2008 165 178